Obiettivo To develop rapid, culture-independent tests for the prediction of drug resistances by PCR-amplification and characterizations of specific mutations within drug resistance-associated target genesTo assess risk factors contributing to MDR-TB in a case-control studyUntil recently, the problem of multidrug-resistant tuberculosis (MDR-TB) in Europe was considered to be negligible, but recent data are indicative of a significant rise of MDR-TB. Several European countries might have reached a turning point of a previously benign situation. Recently, the first major MDR-TB outbreak in Europe was observed in Spain. The situation is aggravated by the uncertainty of risk factors leading to MDR-TB as well as by the long time needed for the identification of MDR by conventional techniques. To take remedial action, this project will develop rapid, culture-independent tests for the prediction of drug resistances by PCR-amplification and characterizations of specific mutations within drug resistance-associated target genes and assess risk factors contributing to MDR-TB in a case-control study.Nested PCR protocols will be applied to amplify directly from sputum samples the drug-resistance associated target genes rpoB, inhA, katG, rrs, rpsL, 23S and gyrA which are involved in resistances to rifampicin, isoniazid, streptomycin, macrolids and fluoroquinolones. Amplification products will be directly sequenced as is already done with the PCR products from cultures. Faster mutation detection techniques - single strand conformation polymorphism (SSCP) and restriction fragment length polymorphism (RFLP), if located on a restriction site - will be tested to replace sequencing of the product as this is usually beyond the scope of a clinical diagnostic laboratory. Campo scientifico medical and health sciencesclinical medicinepneumologytuberculosisnatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Programma(i) FP4-BIOMED 2 - Specific research, technological development and demonstration programme in the field of biomedicine and health, 1994-1998 Argomento(i) 4.2.6 - Disease prevention Invito a presentare proposte Data not available Meccanismo di finanziamento CSC - Cost-sharing contracts Coordinatore LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH Contributo UE Nessun dato Indirizzo 5,Leopoldstrasse 5 80802 MUENCHEN Germania Mostra sulla mappa Costo totale Nessun dato Partecipanti (4) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto RESEARCH CENTER BORSTEL, CENTER FOR MEDICINE AND BIOLOGICAL SCIENCE Germania Contributo UE Nessun dato Indirizzo 18,Parkallee 18 23845 BORSTEL Mostra sulla mappa Costo totale Nessun dato Rijksinstituut voor Volksgezondheid en Milieuhygiene Paesi Bassi Contributo UE Nessun dato Indirizzo 9,A. Van Leeuwenhoeklaan 3720 BA Bilthoven Mostra sulla mappa Costo totale Nessun dato Universidad de Córdoba Spagna Contributo UE Nessun dato Indirizzo S/N,Avenida Menéndez Pidal 14004 Córdoba Mostra sulla mappa Costo totale Nessun dato Université Pierre et Marie Curie - Paris VI Francia Contributo UE Nessun dato Indirizzo 47-83,Boulevard de l'Hôpital 75651 Paris Mostra sulla mappa Costo totale Nessun dato